Umbilical cord mesenchymal stem cells (UC-MSCs) show properties similar to bone marrow mesenchymal stem cells (BM-MSCs), although controversial data exist regarding their osteogenic potential. We prepared clinical-grade UC-MSCs from Wharton's Jelly and we investigated if UC-MSCs could be used as substitutes for BM-MSCs in muscoloskeletal regeneration as a more readily available and functional source of MSCs. UC-MSCs were loaded onto scaffolds and implanted subcutaneously (ectopically) and in critical-sized calvarial defects (orthotopically) in mice. For live cell-tracking experiments, UC-MSCs were first transduced with the luciferase gene. Angiogenic properties of UC-MSCs were tested using the mouse metatarsal angiogenesis assay. Cell secretomes were screened for the presence of various cytokines using an array assay. Analysis of implanted scaffolds showed that UC-MSCs, contrary to BM-MSCs, remained detectable in the implants for 3 weeks at most and did not induce bone formation in an ectopic location. Instead, they induced a significant increase of blood vessel ingrowth. In agreement with these observations, UC-MSC-conditioned medium presented a distinct and stronger proinflammatory/chemotactic cytokine profile than BM-MSCs and a significantly enhanced angiogenic activity. When UC-MSCs were orthotopically transplanted in a calvarial defect, they promoted increased bone formation as well as BM-MSCs. However, at variance with BM-MSCs, the new bone was deposited through the activity of stimulated host cells, highlighting the importance of the microenvironment on determining cell commitment and response. Therefore, we propose, as therapy for bone lesions, the use of allogeneic UC-MSCs by not depositing bone matrix directly, but acting through the activation of endogenous repair mechanisms.
Get full access to this article
View all access options for this article.
References
1.
MauneyJR, PhD, VollochV and KaplanDL. (2005). Role of adult mesenchymal stem cells in bone tissue-engineering applications: current status and future prospects. Tissue Eng, 11:787–802.
2.
El BacklyRM, ZakySH, MuragliaA, TonachiniL, BrunF, CancianiB, ChiapaleD, SantoliniF, CanceddaR and MastrogiacomoM. (2013). A platelet-rich plasma-based membrane as a periosteal substitute with enhanced osteogenic and angiogenic properties: a new concept for bone repair. Tissue Eng Part A, 19:152–165.
3.
GiannoniP, MastrogiacomoM, AliniM, PearceSG, CorsiA, SantoliniF, MuragliaA, BiancoP and CanceddaR. (2008). Regeneration of large bone defects in sheep using bone marrow stromal cells. J Tissue Eng Regen Med, 2:253–262.
4.
QuartoR, MastrogiacomoM, CanceddaR, KutepovSM, MukhachevV, LavroukovA, KonE and MarcacciM. (2001). Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med, 344:385–386.
5.
HassR, KasperC, BöhmS and JacobsR. (2011). Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 9:12.
6.
CapelliC, GottiE, MorigiM, RotaC, WengL, DazziF, SpinelliO, CazzanigaG, TrezziR, et al. (2011). Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy, 13:786–801.
7.
Abu KasimNH, GovindasamyV, GnanasegaranN, MusaS, PradeepPJ, SrijayaTC and AzizZA. (2012). Unique molecular signatures influencing the biological function and fate of post-natal stem cells isolated from different sources. J Tissue Eng Regen Med [Epub ahead of print]; DOI: 10.1002/term.1663.
8.
El OmarR, BeroudJ, StoltzJ-F, MenuP, VelotE and DecotV. (2014). Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies?. Tissue Eng Part B Rev, 20:523–544.
9.
WeissML, AndersonC, MedicettyS, SeshareddyKB, WeissRJ, VanderWerffI, TroyerD and McIntoshKR. (2008). Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells, 26:2865–2874.
10.
TipnisS, ViswanathanC and MajumdarAS. (2010). Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol, 88:795–806.
11.
RibeiroA, LaranjeiraP, MendesS, VeladaI, LeiteC, AndradeP, SantosF, HenriquesA, GrãosM, et al. (2013). Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther, 4:125.
JiYR, YangZX, HanZ-B, MengL, LiangL, FengXM, YangSG, ChiY, ChenDD, WangYW and HanZC. (2012). Mesenchymal stem cells support proliferation and terminal differentiation of B cells. Cell Physiol Biochem, 30:1526–1537.
14.
WuY, CaoY, LiX, XuL, WangZ, LiuP, YanP, LiuZ, WangJ, et al. (2014). Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD. Stem Cell Res, 12:132–138.
15.
DeuseT, StubbendorffM, Tang-QuanK, PhillipsN, KayMA, EiermannT, PhanTT, VolkH-D, ReichenspurnerH, RobbinsRC and SchrepferS. (2011). Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant, 20:655–667.
16.
IntronaM, LucchiniG, DanderE, GalimbertiS, RovelliA, BalduzziA, LongoniD, PavanF, MasciocchiF, et al. (2014). Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant, 20:375–381.
17.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
18.
MajoreI, MorettiP, StahlF, HassR and KasperC. (2011). Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. Stem Cell Rev, 7:17–31.
19.
GirdlestoneJ, LimbaniVA, CutlerAJ and NavarreteC V. (2009). Efficient expansion of mesenchymal stromal cells from umbilical cord under low serum conditions. Cytotherapy, 11:738–748.
20.
Suzdal'tsevaYG, BurunovaVV, VakhrushevIV, YaryginVN and YaryginKN. (2007). Capability of human mesenchymal cells isolated from different sources to differentiation into tissues of mesodermal origin. Bull Exp Biol Med, 143:114–121.
21.
BoschJ, HoubenAP, RadkeTF, StapelkampD, BünemannE, BalanP, BuchheiserA, LiedtkeS and KöglerG. (2012). Distinct differentiation potential of “MSC”. derived from cord blood and umbilical cord: are cord-derived cells true mesenchymal stromal cells?. Stem Cells Dev, 21:1977–1988.
22.
TroyerDL and WeissML. (2008). Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells, 26:591–599.
23.
SchneiderRK, PuellenA, KramannR, RaupachK, BornemannJ, KnuechelR, Pérez-BouzaA and NeussS. (2010). The osteogenic differentiation of adult bone marrow and perinatal umbilical mesenchymal stem cells and matrix remodelling in three-dimensional collagen scaffolds. Biomaterials, 31:467–480.
24.
HsiehJ and FuY. (2010). Functional module analysis reveals differential osteogenic and stemness potentials in human mesenchymal stem cells from bone marrow and Wharton's jelly of umbilical cord. Stem Cells Dev, 19:1896–1910.
25.
BolliniS, GentiliC, TassoR and CanceddaR. (2013). The regenerative role of the fetal and adult stem cell secretome. J Clin Med, 2:302–327.
26.
ShoharaR, YamamotoA, TakikawaS, IwaseA, HibiH, KikkawaF and UedaM. (2012). Mesenchymal stromal cells of human umbilical cord Wharton's jelly accelerate wound healing by paracrine mechanisms. Cytotherapy, 14:1171–1181.
27.
MuragliaA, MartinI, CanceddaR and QuartoR. (1998). A nude mouse model for human bone formation in unloaded conditions. Bone, 22:131S–134S.
28.
IgnowskiJM and SchafferD V. (2004). Kinetic analysis and modeling of firefly luciferase as a quantitative reporter gene in live mammalian cells. Biotechnol Bioeng, 86:827–834.
29.
DagaA, MuragliaA, QuartoR, CanceddaR and CorteG. (2002). Enhanced engraftment of EPO-transduced human bone marrow stromal cells transplanted in a 3D matrix in non-conditioned NOD/SCID mice. Gene Ther, 9:915–921.
30.
KuiperEJ, RoestenbergP, EhlkenC, LambertV, van Treslong-de GrootHB, LyonsKM, AgostiniH-JT, RakicJ-M, KlaassenI, et al. (2007). Angiogenesis is not impaired in connective tissue growth factor (CTGF) knock-out mice. J Histochem Cytochem, 55:1139–1147.
31.
SpicerPP, KretlowJD, YoungS, JansenJA, KasperFK and MikosAG. (2012). Evaluation of bone regeneration using the rat critical size calvarial defect. Nat Protoc, 7:1918–1929.
32.
LaschkeMW, StroheA, MengerMD, AliniM and EglinD. (2010). In vitro and in vivo evaluation of a novel nanosize hydroxyapatite particles/poly(ester-urethane) composite scaffold for bone tissue engineering. Acta Biomater, 6:2020–2027.
33.
(1997). Opinion of the EMEA on the potential risk associated with medicinal products in relation to bovine spongiform encephalopathy (BSE) (16 April 1996) and report from the Committee for Proprietary Medicinal Products (CPMP) on the'Note for Guidance on minimizing the risk of transmitting animal spongiform encephalopathies via medicinal products' (15 April 1997). Adverse Drug React Toxicol Rev, 16:113–121.
34.
TuschongL, SoenenSL, BlaeseRM, CandottiF and MuulLM. (2002). Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther, 13:1605–1610.
35.
WangD, LiJ, ZhangY, ZhangM, ChenJ, LiX, HuX, JiangS, ShiS and SunL. (2014). Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther, 16:R79.
36.
CapelliC, DomenghiniM, BorleriG, BellavitaP, PomaR, CarobbioA, MicòC, RambaldiA, GolayJ and IntronaM. (2007). Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant, 40:785–791.
37.
PetsaA, GarganiS, FelesakisA, GrigoriadisN and GrigoriadisI. (2009). Effectiveness of protocol for the isolation of Wharton's Jelly stem cells in large-scale applications. In Vitro Cell Dev Biol Anim, 45:573–576.
38.
MajoreI, MorettiP, HassR and KasperC. (2009). Identification of subpopulations in mesenchymal stem cell-like cultures from human umbilical cord. Cell Commun Signal, 7:6.
39.
SotiropoulouPA, PerezSA, SalagianniM, BaxevanisCN and PapamichailM. (2006). Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells, 24:462–471.
40.
MartinI, MuragliaA, CampanileG, CanceddaR and QuartoR. (1997). Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow. Endocrinology, 138:4456–4462.
41.
ChevallierN, AnagnostouF, ZilberS, BodivitG, MaurinS, BarraultA, BierlingP, HernigouP, LayrolleP and RouardH. (2010). Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials, 31:270–278.
42.
OhgushiH, MiyakeJ and TateishiT. (2003). Mesenchymal stem cells and bioceramics: strategies to regenerate the skeleton. Novartis Found Symp, 249: 118–127; discussion 127–132, 170–174, 239–241.
43.
MirabellaT, PoggiA, ScaranariM, MogniM, LituaniaM, BaldoC, CanceddaR and GentiliC. (2011). Recruitment of host's progenitor cells to sites of human amniotic fluid stem cells implantation. Biomaterials, 32:4218–4227.
44.
SabapathyV, SundaramB, VmS, MankuzhyP and KumarS. (2014). Human wharton's jelly mesenchymal stem cells plasticity augments scar-free skin wound healing with hair growth. PLoS One, 9:e93726.
45.
MuellerAA, ForrazN, GuevenS, AtzeniG, DegoulO, Pagnon-MinotA, HartmannD, MartinI, ScherberichA and McGuckinC. (2014). Osteoblastic differentiation of Wharton jelly biopsy specimens and their mesenchymal stromal cells after serum-free culture. Plast Reconstr Surg, 134:59e–69e.
46.
GiannoniP, PhD, ScaglioneS, DagaA, IlengoC, SciB, CilliM and QuartoR. (2010). Short-time survival and engraftment of bone marrow stromal cells in an ectopic model of bone regeneration. Tissue Eng Part A, 16:489–499.
47.
PrasannaSJ, GopalakrishnanD, ShankarSR and VasandanAB. (2010). Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One, 5:e9016.
48.
BiancoP, CaoX, FrenettePS, MaoJJ, RobeyPG, SimmonsPJ and WangC-Y. (2013). The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med, 19:35–42.
49.
FongC-Y, ChakL-L, BiswasA, TanJ-H, GauthamanK, ChanW-K and BongsoA. (2011). Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev, 7: 1–16.
50.
Nagamura-InoueT and HeH. (2014). Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells, 6:195–202.
51.
TassoR, GaetaniM, MolinoE, CattaneoA, MonticoneM, BachiA and CanceddaR. (2012). The role of bFGF on the ability of MSC to activate endogenous regenerative mechanisms in an ectopic bone formation model. Biomaterials, 33:2086–2096.
52.
HsiehJ-Y, WangH-W, ChangS-J, LiaoK-H, LeeI-H, LinW-S, WuC-H, LinW-Y and ChengS-M. (2013). Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One, 8:e72604.
53.
BalasubramanianS, VenugopalP, SundarrajS, ZakariaZ, Sen MajumdarA and TaM. (2012). Comparison of chemokine and receptor gene expression between Wharton's jelly and bone marrow-derived mesenchymal stromal cells. Cytotherapy, 14:26–33.
54.
EdwardsSS, ZavalaG, PrietoCP, ElliottM, MartínezS, EgañaJT, BonoMR and PalmaV. (2014). Functional analysis reveals angiogenic potential of human mesenchymal stem cells from Wharton's jelly in dermal regeneration. Angiogenesis, 17:851–866.
55.
NasirGA, MohsinS, KhanM, ShamsS, AliG, KhanSN and RiazuddinS. (2013). Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice. J Transl Med, 11:78.
56.
AmablePR, TeixeiraMVT, CariasRBV, GranjeiroJM and BorojevicR. (2014). Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly. Stem Cell Res Ther, 5:53.
57.
BrancatoSK and AlbinaJE. (2011). Wound macrophages as key regulators of repair: origin, phenotype, and function. Am J Pathol, 178:19–25.
58.
GrantV, KingAE, FaccendaE and KellyRW. (2005). PGE/cAMP and GM-CSF synergise to induce a pro-tolerance cytokine profile in monocytic cell lines. Biochem Biophys Res Commun, 331:187–193.
59.
RocaH, VarsosZS, SudS, CraigMJ, YingC and PientaKJ. (2009). CCL2 and interleukin-6 promote survival of human CD11b+peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem, 284:34342–34354.
